Rapid accumulation in the targeted cancer tissue is desired for the delivery of 211At because of its relatively short half-life (7.2 h), and thus α-MSH analogs are attractive vehicles for the delivery of 211At to metastatic melanoma. Here, STAMBP is linked to metastatic melanoma.